Novartis
www.novartis.com.sgAbout
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. To learn more about Novartis in Singapore, visit https://www.novartis.com.sg
Website: https://www.novartis.com.sg/
Facebook: https://www.facebook.com/novartis
Twitter: https://twitter.com/novartis
Youtube: https://www.youtube.com/channel/UCrOUkNI1eCMumFJ1PK6PaYw
Instagram: http://instagram.com/novartis
Media
Videos
Branches
1Novartis
Key Trials
2 trials shown
Novartis
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
The purpose of the First-In-Human study is to assess safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.
Novartis
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
The purpose of this first in human (FIH) trial is to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in adult patients with advanced solid tumors in selected indications.